Clinical Outcomes in AYAs (Adolescents and Young Adults) Treated with Proton Therapy for Uveal Melanoma: A Comparative Matching Study with Elder Adults.
AYA
PSM
TYA
adolescents
eye tumor
local tumor control
metastasis incidence
propensity score matching
proton therapy
survival
teenagers
uveal melanoma
young adults
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
20 Sep 2023
20 Sep 2023
Historique:
received:
28
07
2023
revised:
13
09
2023
accepted:
15
09
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
The aim of this study was to compare the clinical outcomes of adolescents and young adults (AYAs) with those of elder adult patients treated with proton therapy (PT) for uveal melanoma (UM). A retrospective, comparative study was conducted in UM patients who underwent PT at the Ocular Oncology Unit of the Jules-Gonin Eye Hospital (University of Lausanne, Lausanne, Switzerland) and the Paul Scherrer Institute (PSI); (Villigen, Switzerland) between January 1997 and December 2007. Propensity score matching (PSM) was used to select for each AYA (between 15-39 years old) an elder adult patient (≥40 years) with similar characteristics. We assessed ocular follow-up, local tumor control, metastasis incidence, and overall and relative survival (OS and RS). Non-terminal outcomes were then compared between the two groups using competing risk survival analysis. Out of a total of 2261 consecutive UM patients, after excluding 4 children (<15 years) and 6 patients who were metastatic at presentation, we identified 272 AYA patients and matched 270 of them with 270 elder adult patients. Before PSM, the AYA patients had a higher incidence of primary iris melanoma (4.0% vs. 1.4%; While AYAs treated with PT for UM have similar ocular outcomes and present the same metastasis incidence and OS as elder adults, their RS is worse than that in elder adults, when compared with the population in general.
Identifiants
pubmed: 37760619
pii: cancers15184652
doi: 10.3390/cancers15184652
pmc: PMC10526519
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Ophthalmology. 2016 Apr;123(4):898-907
pubmed: 26854035
Ophthalmology. 2014 Apr;121(4):898-904
pubmed: 24405742
Lifetime Data Anal. 1999;5(1):67-79
pubmed: 10214003
J AAPOS. 2014 Feb;18(1):61-6
pubmed: 24568985
Saudi J Ophthalmol. 2013 Jul;27(3):197-201
pubmed: 24227986
Graefes Arch Clin Exp Ophthalmol. 2006 Dec;244(12):1646-9
pubmed: 16636835
Acta Ophthalmol Scand. 2003 Aug;81(4):389-95
pubmed: 12859267
JAMA Ophthalmol. 2015 Jul;133(7):792-6
pubmed: 25905597
ESMO Open. 2021 Apr;6(2):100096
pubmed: 33926710
JAMA Ophthalmol. 2019 Jan 1;137(1):75-81
pubmed: 30422230
Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):138-47
pubmed: 11516863
Ophthalmology. 2003 May;110(5):956-61
pubmed: 12750097
Eur J Ophthalmol. 2013 Mar-Apr;23(2):208-16
pubmed: 23065853
Retina. 2012 Jul;32(7):1363-72
pubmed: 22466491
ESMO Open. 2017 Sep 8;2(4):e000252
pubmed: 29018578
Biostatistics. 2012 Jul;13(3):371-83
pubmed: 22045910
Retina. 2010 Sep;30(8):1267-71
pubmed: 20224468
J Natl Cancer Inst Monogr. 2014 Nov;2014(49):228-35
pubmed: 25417236
J Clin Epidemiol. 2001 Apr;54(4):387-98
pubmed: 11297888
BMC Ophthalmol. 2022 Jan 3;22(1):6
pubmed: 34980044
Int J Epidemiol. 2015 Oct;44(5):1549-56
pubmed: 26108436
Int J Radiat Oncol Biol Phys. 2003 Mar 15;55(4):867-80
pubmed: 12605964
Arch Ophthalmol. 2000 Jul;118(7):918-23
pubmed: 10900104
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
Ophthalmology. 2011 Sep;118(9):1881-5
pubmed: 21704381
Nat Rev Clin Oncol. 2015 Aug;12(8):465-80
pubmed: 26011488